Leukemia Research
Volume 28, Issue 8 , Pages 805-812 , August 2004

Impaired clonogenic growth of myelodysplastic bone marrow progenitors in vitro is irrelevant to their apoptotic state

Received 8 August 2003 ,Accepted 14 December 2003.

References 

  1. Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia. 1993;7:144–146
  2. Yoshida Y, Stephenson J, Mufti GJ. Myelodysplastic syndromes: from morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia. Int. J. Hematol. 1993;57:87–97
  3. Greenberg PL. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res. 1998;22:1123–1136
  4. Clark DM, Lampert IA. Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective hematopoiesis. Leuk Lymph. 1990;2:415–418
  5. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, et al.  Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995;86:268–276
  6. Bogdanovic AD, Trpinac DP, Jankovic GM, Bumbasirevic VZ, Obradovic M, Colovic MD. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia. 1997;11:656–659
  7. Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ. ‘Low-risk’ myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro-versus anti-apoptotic bcl-2-related proteins. Br. J. Haematol. 1998;103:1075–1082
  8. Tsoplou P, Kouraklis-Symeonidis A, Thanopoulou E, Zikos P, Orphanos V, Zoumbos NC. Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in ‘good’ versus ‘poor’ prognosis patients and correlation with apoptosis-related genes. Leukemia. 1999;13:1554–1563
  9. Matthes TW, Meyer G, Samii K, Beris P. Increased apoptosis in acquired sideroblastic anemia. Br. J. Haematol. 2000;111:843–852
  10. Lepelley P, Campergue L, Grardel N, Preudhomme C, Cosson A, Fenaux P. Is apoptosis a massive process in myelodysplastic syndromes?. Br. J. Haematol. 1996;95:368–371
  11. Choi JW. Apoptotic rate varies with detection methods in myelodysplastic syndromes: impact of method selection. Eur. J. Hematol. 2002;69:62–63
  12. Dar S, Mundle S, Andric T, Qawi H, Shetty V, Reza S, et al.  Biological characteristics of myelodysplastic syndrome patients who demonstrate high versus no intramedullary apoptosis. Eur. J. Hematol. 1999;62:90–94
  13. Irvine AE, Magill MK, Somerville LE, McMullin MF. Spontaneous intramedullary apoptosis is present in disorders other than myelodysplasia. Exp. Hematol. 1998;26:435–439
  14. Yuan J, Angelucci E, Lucarelli G, Aljurf M, Snyder LM, Kiefer CR, et al.  Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley’s anemia). Blood. 1993;82:374–377
  15. Yoshida Y, Kawabata H, Anzai N, Tohyama K. Apoptosis as a cell biological abnormality in myelodysplasia. Pathol. Biol. 1997;45:573–578
  16. Philpott NJ, Scopes J, Marsh JC, Gordon-Smith EC, Gibson FM. Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance. Exp. Hematol. 1995;23:1642–1648
  17. Koh PS, Hughes GC, Faulkner GR, Keeble WW, Bagby RC. The Fanconi anemia group C gene product modulates apoptotic response to tumor necrosis factor-α and fas-ligand but does not suppress expression of the to tumor necrosis factor receptor superfamily. Exp. Hematol. 1999;27:1–8
  18. Perdahl EB, Naprstek BL, Wallace WC, Lipton JM. Erythroid failure in Diamond–Blackfan anemia is characterized by apoptosis. Blood. 1994;83:645–650
  19. Mundle S, Venugopal P, Shetty V, Ali A, Chopra H, Handa H, et al.  The relative extent and propensity of CD34+ vs. CD34− cells to undergo apoptosis in myelodysplastic marrows. Int. J. Hematol. 1999;69:152–159
  20. Pecci A, Travaglino E, Klersy C, Invernizzi R. Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic bone marrow. Acta. Hematol. 2003;109:29–34
  21. Ruutu T, Partanen S, Lintula R, Teerenhovi L, Knuutila S. Erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes. Scand. J. Haematol. 1984;32:395–402
  22. Ohmori M, Ohmori S, Ueda Y, Yoshida Y, Okuma M. Ineffective hemopoiesis in the myelodysplastic syndromes (MDS) as studied by daily in situ observation. Int. J. Cell Cloning. 1991;9:521–530
  23. Dan K, An E, Futaki M, Inokuchi K, Gomi S, Yamada T, et al.  Megakaryocyte, erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes. Acta Haematol. 1993;89:113–118
  24. Flores-Figueroa E, Gutierrez-Espindola G, Guerrero-Rivera S, Pizzuto-Chavez J, Mayani H. Hematopoietic progenitor cells from patients with myelodysplastic syndromes: in vitro colony growth and long-term proliferation. Leuk Res. 1999;23:385–394
  25. McMullin MF, Buckley O, Magill MK, Irvine AE. Long-term bone marrow culture profiles in patients with myelodysplastic syndromes are not explicable by defective apoptosis. Leuk Res. 1998;22:735–740
  26. Koopman G, Reutelingsperger CPM, Kuijten GAM, Keehnen RMJ, Pals ST, Van Oers MHJ. Annexin-V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84:1415–1420
  27. Petit PX, Zamzami N, Vayssière J-L, Mignotte B, Kroemer G, Castedo M. Implication of mitochondria in apoptosis. Mol. Cell Biochem. 1997;174:185–188
  28. Rutella S, Rumi C, Pierelli L, Morosetti R, Sica S, Bonanno G, et al.  Granulocyte colony-stimulating factor perturbs lymphocyte mitochondrial function and inhibits cell cycle progression. Exp. Hematol. 2000;28:612–625
  29. Westwood NB, Mufti GJ. Apoptosis in the myelodysplastic syndromes. Curr. Hematol. Rep. 2003;2:186–192
  30. Saberwal G, Broderick E, Jansen I, Shetty V, Alvi S, Lisak L, et al.  Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes. J. Hematother Stem. Cell Res. 2003;12:443–450
  31. Darzynkiewicz Z, Bedner E, Traganos F. Difficulties and pitfalls in analysis of apoptosis, Methods Cell Biol 2001;63:527-546.
  32. Stahelin BJ, Marti U, Solioz M, Zimmermznn H, Reichen J. False positive staining in the TUNEL assay to detect apoptosis in liver and intestine is caused by endogenous nucleases and inhibited by diethyl pyrocarbonate. Mol. Pathol. 1998;51:204–208
  33. Kockx MM, Muhring J, Knaapen MW, de Meyer GR. RNA synthesis and splicing interferes with DNA in situ end labelling techniques used to detect apoptosis. Am. J. Pathol. 1998;152:885–888
  34. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate between apoptosis, necrosis and autolytic cell death: a cautionary note. Hepatology. 1995;21:1465–1468
  35. Darzynkiewicz Z, Bedner E, Smolewski P. Flow cytometry in analysis of cell cycle and apoptosis. Semin Hematol. 2001;38:179–193
  36. Yoshida Y, Anzai N, Kawabata H. Apoptosis in myelodysplasia: a paradox or a paradigm. Leuk Res. 1995;19:887–891
  37. Denecker G, Dooms H, Van Loo G, Vercammen D, Grooten J, Fiers W, et al.  Phosphatidyl serine exposure during apoptosis precedes release of cytochrome c and decrease in mitochondrial transmembrane potential. FEBS Lett. 2000;465:47–52
  38. Roy S, Nicholson DW. Cross-talk in cell death signaling. J. Exp. Med. 2000;192:F21–F25
  39. Vaughan ATM, Betti CJ, Villalobos MJ. Surviving apoptosis. Apoptosis. 2002;7:173–177
  40. Hoeppner DJ, Hengartner MO, Schnabel R. Engulfment genes cooperate with ced-3 to promote cell death in Caenorhabditis elegans. Nature. 2001;412:202–206
  41. Reddien PW, Cameron S, Horvitz HR. Phagocytosis promotes programmed cell death in C. elegans, Nature 2001: 412–198–202.
  42. Hammill AK, Uhr JW, Scheuermann RH. Annexin-V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Exp. Cell Res. 1999;251:16–21
  43. Span LFR, Pennings AHM, Vierwinden G, Boezeman JBM, Raymakers RAP, de Witte T. The dynamic process of apoptosis analyzed by flow cytometry using Annexin-V/propidium iodide and a modified in situ end labeling technique. Cytometry. 2002;47:24–31
  44. Bouscary D, Chen YL, Guesnu M, Picard F, Viguier F, Lacombe C, et al.  Activity of the caspase-3/CPP32 enzyme is increased in “early-stage” myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro. Exp Hematol. 2000;28:784–791
  45. Bowen DT, Denzlinger C, Brugger W, Culligan D, Gelly K, Adlakha S, et al.  Poor response rate to a continuous schedule of Amifostine therapy for ‘low/intermediate risk’ myelodysplastic patients. Br. J. Haematol. 1998;103:785–787
  46. Tefferi A, Elliot MA, Steensma DP, Hook CC, Dispenzieria A, Hanson CA, et al.  Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk Res. 2001;25:183–185
  47. Nemunaitis J, Rosenfeld C, Getty L, Boegel F, Meyer W, Jennings LW, et al.  Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial. Am. J. Clin. Oncol. 1995;18:189–193
  48. Rosenfeld C, Bedell C. Pilot study of recombinant human soluble tumor necrosos factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome. Leuk Res. 2002;26:721–724

PII: S0145-2126(03)00420-X

doi: 10.1016/j.leukres.2003.12.004

Leukemia Research
Volume 28, Issue 8 , Pages 805-812 , August 2004

Article Tools

* Image Usage & Resolution